BillionToOne counsel sells 20K shares at ~$96–101
BillionToOne’s general counsel exercised options for 20,000 shares and sold an equal number in Rule 10b5-1 plan trades around $96–$101 on September 8, 2026.
Rhea-AI Filing Summary
BillionToOne, Inc. insider Thomas P. Lynch, the General Counsel, Chief Compliance Officer and Secretary, reported option exercises and related share sales on September 8, 2026. He exercised options covering 20,000 shares of Class A Common Stock at exercise prices of $8.65, $11.55, $17.12 and $30.78 per share, all from previously disclosed, fully vested grants.
On the same date, he sold a total of 20,000 shares of Class A Common Stock in a series of open-market transactions at prices generally around $96–$101 per share, with several reported as weighted-average prices over stated intraday ranges. All transactions were made under a Rule 10b5-1 trading plan adopted on June 8, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F12 | 11,042 | $8.65 | $96K |
| Exercise | Stock Option (right to buy) F12 | 3,969 | $11.55 | $46K |
| Exercise | Stock Option (right to buy) F12 | 1,663 | $17.12 | $28K |
| Exercise | Stock Option (right to buy) F12 | 3,326 | $30.78 | $102K |
| Exercise | Class A Common Stock F1 | 11,042 | $8.65 | $96K |
| Exercise | Class A Common Stock F1 | 3,969 | $11.55 | $46K |
| Exercise | Class A Common Stock F1 | 1,663 | $17.12 | $28K |
| Exercise | Class A Common Stock F1 | 3,326 | $30.78 | $102K |
| Sale | Class A Common Stock F1 | 38 | $96.4739 | $4K |
| Sale | Class A Common Stock F1, F2 | 1,944 | $98.9662 | $192K |
| Sale | Class A Common Stock F1, F3 | 8,285 | $100.1228 | $830K |
| Sale | Class A Common Stock F1, F4 | 775 | $100.8289 | $78K |
| Sale | Class A Common Stock F1, F5 | 614 | $98.9986 | $61K |
| Sale | Class A Common Stock F1, F3 | 2,997 | $100.1135 | $300K |
| Sale | Class A Common Stock F1, F6 | 358 | $100.8234 | $36K |
| Sale | Class A Common Stock F1, F7 | 385 | $99.223 | $38K |
| Sale | Class A Common Stock F1, F8 | 1,131 | $100.3261 | $113K |
| Sale | Class A Common Stock F1, F9 | 147 | $101.4077 | $15K |
| Sale | Class A Common Stock F1, F2 | 576 | $98.8882 | $57K |
| Sale | Class A Common Stock F1, F10 | 2,518 | $100.1959 | $252K |
| Sale | Class A Common Stock F1, F11 | 232 | $100.9242 | $23K |
Footnotes (12)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.340 to $99.230 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.585 to $100.565 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.620 to $100.9125 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.340 to $99.195 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.720 to $100.9025 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.830 to $99.825 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.830 to $100.790 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.890 to $101.870 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.670 to $100.550 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.725 to $101.650 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F12. The options are fully vested and exercisable. The terms of the underlying option grant are as previously reported on the Reporting Person's Form 3 filed on November 5, 2025.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Class A Common Stock financial
fully vested and exercisable financial
FAQ
What did BLLN insider Thomas P. Lynch report in this Form 4?
At what prices were Thomas P. Lynch’s BLLN options exercised?
Were the BLLN trades made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.